معرفی
Dr. Paul Nagtegaal serves as a Researcher in the Department of Otorhinolaryngology and Head and Neck Surgery at Erasmus MC in Rotterdam, Netherlands, conducting clinical investigations with emphasis on surgical complications, infection control, and skull base disorders. His institutional affiliation positions him within a leading European medical center specializing in complex head and neck pathologies.
His research portfolio centers on Otorhinolaryngology and Head and Neck Surgery with pronounced focus on Infectious Diseases and Antibiotics stewardship, evidenced by high-impact publications on surgical site infections and bacteriophage therapy. Additional specialties include Retrospective Studies methodology, Skull Base Surgery complications, and Rhinology disorders such as cerebrospinal fluid leaks. His fingerprint analysis confirms deep engagement with Immunoglobulin G4 Related Disease, Sphenoidal Sinus pathologies, and Visual Impairment management within ENT contexts.
Analysis of his 2023-2025 publications reveals a cohesive trajectory in retrospective clinical investigation, particularly examining infection patterns in lacrimal surgery, skull base defect etiologies, and ENT screening protocols for transplant patients. His work demonstrates strong methodological consistency through multicenter collaborations and rigorous cohort analyses, with significant translational impact in antibiotic alternatives and surgical complication prevention.
Scientific recognition includes substantial media coverage, with 14 news outlets and 6 blogs highlighting his bacteriophage therapy research in Nature Microbiology, alongside 251 X platform discussions and 279 Mendeley readers. His 2024 phage therapy study alone garnered 125 Scopus citations within months of publication.
Dr. Nagtegaal has supervised doctoral research as indicated by the "Supervised Work (1)" metric, though specific student names remain unlisted. His collaborative network spans 81 co-authors across 6 continents in the bacteriophage study, suggesting active participation in international grant consortia despite no explicit funding details appearing in the profile.
